We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review
Read MoreHide Full Article
Omeros Corporation (OMER - Free Report) announced that the FDA has extended the review period of a biologics license application (“BLA”) for its lead MASP-2 inhibitor, narsoplimab, by three months. The BLA is seeking approval for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
As a result, the regulatory body will now announce its decision on Oct 17, 2021, instead of the previously anticipated Jul 17, 2021. The extension of the review period is due to additional time required by the FDA for the review.
Shares of Omeros were down 10.7% on Thursday following the announcement of the news. However, the stock has increased 6% so far this year compared with the industry’s rise of 2.4%.
We remind investors, that in January 2021, the BLA for narsoplimab in HSCT-TMA was accepted for filing under the FDA’s Priority Review program.
Per the press release, the company has submitted a response to an FDA information request, which is part of the ongoing BLA Priority Review. The regulatory body classified the response as a major amendment which will require additional time to review.
Currently there is no approved treatment available for HSCT-TMA. Narsoplimab is the first candidate submitted to the FDA for approval for the given indication. Narsoplimab already enjoys a Breakthrough Therapy and Orphan designations to treat HSCT-TMA.
If approved for HSCT-TMA, narsoplimab can lend a big boost to the company’s growth prospects in the days ahead.
We note that narsoplimab is also being evaluated in several late-stage studies for other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. The candidate also enjoys an Orphan and Breakthrough Therapy designation to treat IgA nephropathy.
Athenex’s loss per share estimates have narrowed 21.8% for 2021 and 23.2% for 2022 over the past 60 days.
Avid Bioservices’ earnings estimates have been revised 80% upward for 2021 and 53.8% upward for 2022 over the past 60 days. The stock has soared 74.1% year to date.
Adaptive Biotechnologies’ loss per share estimates have narrowed 11.7% for 2021 and 2.3% for 2022 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review
Omeros Corporation (OMER - Free Report) announced that the FDA has extended the review period of a biologics license application (“BLA”) for its lead MASP-2 inhibitor, narsoplimab, by three months. The BLA is seeking approval for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
As a result, the regulatory body will now announce its decision on Oct 17, 2021, instead of the previously anticipated Jul 17, 2021. The extension of the review period is due to additional time required by the FDA for the review.
Shares of Omeros were down 10.7% on Thursday following the announcement of the news. However, the stock has increased 6% so far this year compared with the industry’s rise of 2.4%.
We remind investors, that in January 2021, the BLA for narsoplimab in HSCT-TMA was accepted for filing under the FDA’s Priority Review program.
Per the press release, the company has submitted a response to an FDA information request, which is part of the ongoing BLA Priority Review. The regulatory body classified the response as a major amendment which will require additional time to review.
Currently there is no approved treatment available for HSCT-TMA. Narsoplimab is the first candidate submitted to the FDA for approval for the given indication. Narsoplimab already enjoys a Breakthrough Therapy and Orphan designations to treat HSCT-TMA.
If approved for HSCT-TMA, narsoplimab can lend a big boost to the company’s growth prospects in the days ahead.
We note that narsoplimab is also being evaluated in several late-stage studies for other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. The candidate also enjoys an Orphan and Breakthrough Therapy designation to treat IgA nephropathy.
Zacks Rank & Stocks to Consider
Omeros currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the healthcare sector include Athenex, Inc. , Avid Bioservices, Inc. (CDMO - Free Report) and Adaptive Biotechnologies Corporation (ADPT - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Athenex’s loss per share estimates have narrowed 21.8% for 2021 and 23.2% for 2022 over the past 60 days.
Avid Bioservices’ earnings estimates have been revised 80% upward for 2021 and 53.8% upward for 2022 over the past 60 days. The stock has soared 74.1% year to date.
Adaptive Biotechnologies’ loss per share estimates have narrowed 11.7% for 2021 and 2.3% for 2022 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>